Evidence map›Paper›PMID 41964038›Full record

ArticleOrphanet journal of rare diseases2026

Prime editing of the common Familial Dysautonomia-causing c.2204 + 6T > C splicing mutation.

Laura Peretto, Mirko Pinotti, Dario Balestra

Abstract readLetter
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laura PerettoDepartment of Life Sciences and Biotechnology, Laboratory for Advanced Therapies (LTTA), and Laboratory for Advanced Therapies (LTTA), Via Fossato di Mortara 74, Ferrara, 44121, Italy.
Mirko PinottiDepartment of Life Sciences and Biotechnology, Laboratory for Advanced Therapies (LTTA), and Laboratory for Advanced Therapies (LTTA), Via Fossato di Mortara 74, Ferrara, 44121, Italy. pnm@unife.it.
Dario BalestraDepartment of Life Sciences and Biotechnology, Laboratory for Advanced Therapies (LTTA), and Laboratory for Advanced Therapies (LTTA), Via Fossato di Mortara 74, Ferrara, 44121, Italy. blsdra@unife.it.ORCID http://orcid.org/0000-0002-6675-9429

Funding

H2020 Excellent Science E93C22001080001Università degli Studi di Ferrara Università degli Studi di Ferrara
6 · The paper itself

Abstract

Familial Dysautonomia (FD, OMIM #223900) is a rare, life-threatening autosomal recessive neuropathy caused in 99.8% of patients by the c.2204 + 6T > C intronic mutation in the ELP1/IKAP gene. This substitution induces exon 20 skipping, leading to reduced ELP1 expression. While splicing-modulating therapies have shown partial efficacy, a permanent genetic correction remains unavailable. Here, we report the first application of Prime Editing (PE) to rescue the FD-causing IKAP splicing defect. Using a mutant exon-trapping minigene (pTB-IKAP) transiently co-transfected in HEK293T cells with PE2 or PE3 components, we demonstrate a significant increase in exon 20 inclusion, from 19 ± 2% to 48 ± 3% and 60 ± 3%, respectively. Restriction fragment length polymorphism and Sanger sequencing confirmed correction of the mutant allele, with PE3 achieving ~ 10% genomic editing efficiency. Moreover, by targeting ESS2 via a silent A > G substitution, we similarly restored exon inclusion to 50 ± 4%. These findings provide proof-of-principle that prime editing, particularly PE3, can efficiently correct or bypass the ELP1/IKAP c.2204 + 6T > C mutation and restore proper splicing. Given that modest increases in ELP1 expression (5-10% of wild-type) markedly alleviate FD severity in mouse models, our results highlight PE as a promising, potentially curative approach and lay the foundation for future ex-vivo and in vivo studies.

Indexed as

Carrier ProteinsDysautonomia, FamilialGene EditingMutationAnimalsExonsHEK293 CellsHumansMiceRNA SplicingCarrier ProteinsFamilial DysautonomiaIKAP c.2204 + 6t > c mutationPrime editing

Identifiers

PMID41964038
PMCPMC13067553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.